Idaho is currently home to 357 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clinical Validation Study of the Eximis CS (Contained Segmentation) System
NCT06572163
Recruiting
The purpose of this study is to evaluate device safety and effectiveness of the Eximis CS System.
Gender:
FEMALE
Ages:
Between 21 years and 49 years
Trial Updated:
03/10/2025
Locations: Rosemark Womens Care Specialists, Idaho Falls, Idaho
Conditions: Laparoscopic Gynecological Surgical Procedures
Register for Updates
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182
Recruiting
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Snake River Research, Idaho Falls, Idaho
Conditions: Clostridioides Difficile Infection
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/10/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Breast Cancer
Register for Updates
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
NCT06377930
Recruiting
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Consultants in Epilepsy and Neurology, PLLC, Boise, Idaho
Conditions: Focal Onset Seizures
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Velcocity Clinical Research, Meridian, Idaho
Conditions: SARS-CoV-2
Register for Updates
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094
Recruiting
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Gender:
ALL
Ages:
Between 10 years and 30 years
Trial Updated:
03/07/2025
Locations: Velocity Clinical Research, Meridian, Idaho
Conditions: Epstein-Barr Virus Infection
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Northwest Clinical Trials, Boise, Idaho
Conditions: Obsessive-Compulsive Disorder
Register for Updates
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
NCT06602232
Recruiting
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Dren Investigational Site, Meridian, Idaho
Conditions: Alopecia Areata, Vitiligo
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: Velocity Clinical Research, Meridian, Idaho
Conditions: Major Depressive Disorder
Register for Updates
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
NCT06862791
Recruiting
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2025
Locations: Research Site, Meridian, Idaho
Conditions: Obesity or Overweight
Register for Updates
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NCT05408845
Recruiting
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Register for Updates
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
NCT04192591
Recruiting
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
03/04/2025
Locations: North Idaho Day Surgery, Post Falls, Idaho
Conditions: Lumbar Spinal Stenosis
Register for Updates